# Optical and Biochemical Biomarkers in Early Pancreatic Cancer

> **NCT03404661** · — · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 346 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Synthetic Human Secretin

## Key facts

- **NCT ID:** NCT03404661
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-11
- **Primary completion:** 2022-03-10
- **Final completion:** 2022-03-10
- **Target enrollment:** 346 (ACTUAL)
- **Last updated:** 2023-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03404661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03404661, "Optical and Biochemical Biomarkers in Early Pancreatic Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03404661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*